SecBot SecBot

OLMA drug pipeline

Olema Oncology, Inc. · 2 rated drugs
$7.36
−2.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.

palazestrant Updated Nov 10

What to watch

The next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.

Bull case
  • Palazestrant has a differentiated dual mechanism as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), which the company believes may offer superior efficacy versus pure SERDs like elacestrant or giredestrant.
  • The analyst consensus is Strong Buy (16 Buy/Strong Buy vs 2 Hold, 0 Sell) with a mean price target of $36.50, implying roughly 400% upside from the current ~$7.27 price, reflecting high expectations for the OPERA-01 readout.
  • Roche's positive Phase 3 data for giredestrant (Lidera/EvERA trials) in 2025 validated the oral SERD class and sent OLMA shares up over 100% in a single day, showing the stock's extreme sensitivity to positive class-level signals.
Bear case
  • Palazestrant is a single-product pipeline for a clinical-stage company with no approved drugs and a net loss of $73.6M in Q3 2026 alone, meaning significant shareholder dilution risk if the OPERA-01 readout is delayed or negative.
  • The oral SERD/CERAN class is increasingly crowded: Roche's giredestrant has positive Phase 3 data, AstraZeneca's camizestrant is advancing, and elacestrant (Orserdu) is already approved. Palazestrant needs to show clear differentiation to capture meaningful market share.
  • Short interest is very high at ~19.6% of outstanding shares (11.9 days to cover as of Oct 30, 2026), reflecting substantial bearish conviction that the drug may fail or underwhelm.
● neutral
Impact
PhasePhase 1/1b/2
Time to marketOP-3136 is in Phase 1/1b/2 clinical trials. If development proceeds successfully, a potential approval would likely be several years away, contingent on completing Phase 2/3 trials.

OP-3136 Updated Nov 10

What to watch

The next catalyst for OP-3136 is the SABCS presentation in December 2026, where combination data with palazestrant will be shown. Positive data could support the combination strategy and boost confidence in the broader pipeline, but the stock's primary near-term binary is the Phase 3 OPERA-01 palazestrant readout expected in Q1 2027. OP-3136 remains an early-stage pipeline asset, and its data at SABCS is unlikely to be a standalone stock-moving event.

Bull case
  • Initial Phase 1 monotherapy data at ASCO 2026 showed OP-3136 was well-tolerated with no dose-limiting toxicities and no treatment-related discontinuations, a clean safety profile.
  • Nearly two-thirds of evaluable patients experienced tumor shrinkage across multiple solid tumor types, suggesting broad anti-tumor activity.
  • Preclinical data showed synergistic anti-tumor activity when OP-3136 is combined with palazestrant in ER+/HER2- breast cancer models, supporting a combination strategy.
Bear case
  • OP-3136 is still in early-stage Phase 1/1b/2 development; the drug is years away from any regulatory filing or approval.
  • KAT6 inhibitors are a novel mechanism with no approved drugs in the class, so clinical proof-of-concept remains unvalidated.
  • Olema's stock has fallen sharply from its 52-week high of $36.26 to $7.27, reflecting investor disappointment over the OPERA-01 data delay into 2027 and institutional exits by RA Capital, Jennison, and Polar Capital.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
palazestrantA Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerPhase 2Completed · results153Jul 30, 2024